Global Paclitaxel Sales Market Report 2020 by Manufacturer, Region, Type and Application By Innovation Market Research, Inc

 Pulichser: XYZResearch

November 2019

 Pages: 117

 IMR 6247

Global paclitaxel market was valued at 78.77 Million USD in 2017 and will reach 161.66 Million USD by the end of 2025, growing at a CAGR of 9.4% during 2019-2025. Paclitaxel is a white crystalline powder, odorless and tasteless. It is insoluble in water and soluble in chloroform, acetone and other organic solvents. The report is revolving around Paclitaxel active pharmaceutical ingredients.

Paclitaxel is a mitotic inhibitor used in Cancer chemotherapy; Paclitaxel was discovered in 1962 as a result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it ""taxol"".

The classification of Paclitaxel includes Natural Paclitaxel API and Semi-synthetic Paclitaxel API, and the proportion of Natural Paclitaxel API in 2017 was about 31%, and the proportion was decreasing trend from 2012 to 2017.

Paclitaxel is widely sales for Ovarian Cancer, Cervical Cancer, Breast Cancer and Others. The most proportion of Paclitaxel was sales in Ovarian Cancer, and the consumption proportion was about 46% in 2017.

North America was the largest consumption place, with a consumption market share nearly 53% in 2017. Europe was the second largest consumption place with the consumption market share of 19%, China was also an important sales region for the Paclitaxel.

Market competition is intense. Phyton, ScinoPharm, Novasep, Samyang, etc. are the leaders of the industry. They hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.

Geographically, this report split global into several key Regions, with sales (K Units), revenue (M USD), market share and growth rate of Paclitaxel for these regions, from 2012 to 2023 (forecast), covering
Southeast Asia
South America

Global Paclitaxel market competition by top manufacturers/players, with Paclitaxel sales volume, Price (USD/Unit), revenue (M USD) and market share for each manufacturer/player.

The top players including
TAPI (Teva)
Huiang biopharma
Yunnan Hande
Hainan Yew Pharm
Jiangsu Yew Biotechnology

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Natural Paclitaxel API
Semi-synthetic Paclitaxel API

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Paclitaxel for each application, including
Ovarian Cancer
Cervical Cancer
Breast Cancer

If you have any special requirements, please let us know and we will offer you the report as you want.

Please fill in the form below to Request for Customized Report
Your personal details are safe and secured with us. Privacy Policy

To request sample copy of this report, please complete the form below verified and secure

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Your personal details are safe and secured with us. Privacy Policy

    What Information does this report contain?

Purchase Options

Offers & Discounts

  • Chapter purchase
  • Historical market data
  • Country level data breakdown
  • Free customization*
  • Discounts for first time
  • Special pricing for
              non-business entities


  • We offer 20% free customization on every purchase.

Get in touch!

  +91 810 895 3541